CTLA-4 blockade in tumor models: An overview of preclinical and translational research

Cancer Immunity

Volumn 13, Issue 1, 2013, Pages

  Grosso, Joseph F ^a   Jure Kunkel, Maria N ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antibody; Co stimulation; CTLA 4; Preclinical; T cell

Indexed keywords

ALPHA2B INTERFERON; BASILIXIMAB; CARBOPLATIN; CD40 LIGAND MONOCLONAL ANTIBODY; CISPLATIN; CORTICOSTEROID; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DACTINOMYCIN; DENDRITIC CELL VACCINE; ETOPOSIDE; FOTEMUSTINE; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; IXABEPILONE; LEUPRORELIN; MELPHALAN; PACLITAXEL; PEMETREXED; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; TICILIMUMAB; UNINDEXED DRUG; VEMURAFENIB; ANTIBODY; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANTIGEN EXPRESSION; BLADDER TUMOR; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; BREAST TUMOR; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL RESEARCH; COLON TUMOR; COLORECTAL TUMOR; DIARRHEA; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; FATIGUE; FIBROSARCOMA; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; LYMPHOMA; MELANOMA; METASTATIC MELANOMA; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; OVARY TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMACYTOMA; PROSTATE CANCER; PROSTATE TUMOR; PRURITUS; REVIEW; TRANSITIONAL CELL CARCINOMA; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MODEL; TUMOR XENOGRAFT; UVEA MELANOMA; ANIMAL; CO-STIMULATION; CTLA-4; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; PRECLINICAL; T LYMPHOCYTE;

ANTIBODY; CO-STIMULATION; CTLA-4; PRECLINICAL; T CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84873129546     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674. (PMID: 21376230)
2. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111. (PMID: 11323675)
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570. (PMID: 21436444)
4. TM (ipilimumab) [US package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
5. TM (ipilimumab) [EU package insert]. Anagni, Italy: Bristol-Myers Squibb S.r.l.; 2011.
6. TM (ipilimumab) [Australia package insert]. Noble Park, Victoria: Bristol-Myers Squibb Pty Ltd.; 2011.
7. Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2011; 17: 4622-4628. (PMID: 21467163)
8. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009; 229: 67-87. (PMID: 19426215)
9. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29-37. (PMID: 19043418)
10. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, Hipkiss E, Vignali DA, Pardoll DM, Drake CG. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009; 182: 6659-6669. (PMID: 19454660)
11. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3: 939-951. (PMID: 14647476)
12. Linsley PS. Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation? J Exp Med 1995; 182: 289-292. (PMID: 7543133)
13. Alegre ML, Noel PJ, Eisfelder BJ, Chuang E, Clark MR, Reiner SL, Thompson CB. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 1996; 157: 4762-4770. (PMID: 8943377)
14. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-618. (PMID: 12087419)
15. Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, Stuart DI, van der Merwe PA, Davis SJ. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201-210. (PMID: 12196291)
16. van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and fast kinetics. J Exp Med 1997; 185: 393-403. (PMID: 9053440)
17. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Fal-orni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puc-cetti P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-1101. (PMID: 12368911)
18. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bian-chi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4: 1206-1212. (PMID: 14578884)
19. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mel-lor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-1372. (PMID: 10224276)
20. Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygen-ase. Int Immunol 2004; 16: 1391-1401. (PMID: 15351783)
21. Orabona C, Grohmann U, Belladonna ML, Fallarino F, Vacca C, Bianchi R, Bozza S, Volpi C, Salomon BL, Fioretti MC, Roamani L, Puccetti P. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004; 5: 1134-1142. (PMID: 15467723)
22. Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA- 4) induces transforming growth factor p (TGF-p) production by murine CD4+ T cells. J Exp Med 1998; 188: 1849-1857. (PMID: 9815262)
23. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-569. (PMID: 1714933)
24. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413. (PMID: 7882171)
25. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000; 164: 5015-5018. (PMID: 10799854)
26. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LS, Sansom DM. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332: 600-603. (PMID: 21474713)
27. Chuang E, Fisher TS, Morgan RW, Robbins MD, Duerr JM, Vander Heiden MG, Gardner JP, Hambor JE, Neveu MJ, Thompson CB. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 2000; 13: 313-322. (PMID: 11021529)
28. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T cell activation by distinct mechanisms. Mol Cell Biol 2005; 25: 9543-9553. (PMID: 16227604)
29. Marengère LE, Waterhouse P, Duncan GS, Mittrücker HW, Feng GS, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996; 272: 1170-1173. (PMID: 8638161)
30. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7: 445-450. (PMID: 9354465)
31. Vijayakrishnan L, Slavik JM, Illés Z, Greenwald RJ, Rainbow D, Greve B, Peterson LB, Hafler DA, Freeman GJ, Sharpe AH, Wicker LS, Kuchroo VK. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 2004; 20: 563-575. (PMID: 15142525)
32. Araki M, Chung D, Liu S, Rainbow DB, Chamberlain G, Garner V, Hunter KM, Vijayakrishnan L, Peterson LB, Oukka M, Sharpe AH, Sobel R, Kuchroo VK, Wicker LS. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. J Immunol 2009; 183: 5146-5157. (PMID: 19783679)
33. Chikuma S, Abbas AK, Bluestone JA. B7-independent inhibition of T cells by CTLA-4. J Immunol 2005; 175: 177-181. (PMID: 15972645)
34. Choi JM, Kim SH, Shin JH, Gibson T, Yoon BS, Lee DH, Lee SK, Bothwell AL, Lim JS, Lee SK. Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis. Proc Natl Acad Sci U S A 2008; 105: 19875-19880. (PMID: 19066215)
35. Choi JM, Ahn MH, Chae WJ, Jung YG, Park JC, Song HM, Kim YE, Shin JA, Park CS, Park JW, Park TK, Lee JH, Seo BF, Kim KD, Kim ES, Lee DH, Lee SK, Lee SK. Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med 2006; 12: 574-579. (PMID: 16604087)
36. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, Wei B, Hogg N, Garside P, Rudd CE. Reversal of the TCR stop signal by CTLA-4. Science 2006; 313: 1972-1975. (PMID: 16931720)
37. Schneider H, Valk E, da Rocha Dias S, Wei B, Rudd CE. CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function. Proc Natl Acad Sci U S A 2005; 102: 12861-12866. (PMID: 16126897)
38. Yokosuka T, Kobayashi W, Takamatsu M, Sakata-Sogawa K, Zeng H, Hashimoto-Tane A, Yagita H, Tokunaga M, Saito T. Spatiotem-poral basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity 2010; 33: 326-339. (PMID: 20870175)
39. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275. (PMID: 18845758)
40. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11: 852-863. (PMID: 22116087)
41. Water house P, Penninger J M, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985-988. (PMID: 7481803)
42. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547. (PMID: 7584144)
43. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural analysis of CTLA-4 function in vivo. J Immunol 2000; 164: 5319-5327. (PMID: 10799894)
44. Mandelbrot DA, McAdam AJ, Sharpe AH. B7-1 and B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med 1999; 189: 435-440. (PMID: 9892625)
45. Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer J 2010; 16: 311-317. (PMID: 20693841)
46. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 1997; 7: 885-895. (PMID: 9430233)
47. Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur J Immunol 1998; 28: 3137-3143. (PMID: 9808182)
48. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte anti-gen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A 1999; 96: 8603-8608. (PMID: 10411922)
49. Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A, Mandelbrot DA, Boussiotis VA, Sharpe AH. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002; 32: 366-373. (PMID: 11807776)
50. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6: 411-417. (PMID: 9133420)
51. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates induction of anergy in vivo. Immunity 2001; 14: 145-155. (PMID: 11239447)
52. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shi-mizu J, Takahashi T, Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27. (PMID: 16903903)
53. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007; 8: 457-462. (PMID: 17440451)
54. Rudolph M, Hebel K, Miyamura Y, Maverakis E, Brunner-Weinzierl MC. Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivo. J Immunol 2011; 186: 5580-5589. (PMID: 21478403)
55. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A 2011; 108: 266-271. (PMID: 21173239)
56. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T cell function. Clin Cancer Res 2007; 13: 2158-2167. (PMID: 17404100)
57. Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, Sutmuller RP, Adema GJ. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121: 95-105. (PMID: 17315190)
58. Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T. Enhanced induction of anti-tumor T cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997; 57: 4036-4041. (PMID: 9307290)
59. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötter-man TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010; 33: 225-235. (PMID: 20445343)
60. Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z. Diamond DJ, Ellenhorn JD. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003; 170: 3401-3407. (PMID: 12626601)
61. Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ, Ellenhorn JD. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res 2004; 64: 5407-5414. (PMID: 15289349)
62. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15: 5379-5388. (PMID: 19706802)
63. Pilones KA, Kawashima N, Yang AM, Babb JS, Formenti SC, Demaria S. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res 2009; 15: 597-606. (PMID: 19147765)
64. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11: 728-734. (PMID: 15701862)
65. Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MW, Yoshizawa H, Yagita H, Gejyo F, Okumura K, Smyth MJ. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol 2010; 184: 5493-5501. (PMID: 20400706)
66. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade syner-gizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998; 95: 10067-10071. (PMID: 9707601)
67. Jure-Kunkel MN, Masters G, Girit E, Dito G, Lee FY. Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in combination with ixabepilone in preclinical tumor models [abstract]. J Clin Oncol 2008; 26 Suppl 15: 3048.
68. Saha A, Chatterjee SK. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand J Immunol 2010; 71: 70-82. (PMID: 20384858)
69. Lute KD, May KF Jr, Lu P, Zhang H, Kocak E, Mosinger B, Wolford C, Phillips G, Caligiuri MA, Zheng P, Liu Y. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 2005; 106: 3127-3133. (PMID: 16037385)
70. Pedersen AE, Buus S, Claesson MH. Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer Lett 2006; 235: 229-238. (PMID: 15927356)
71. Kocak E, Lute K, Chang X, May KF Jr, Exten KR, Zhang H, Abdes-salam SF, Lehman AM, Jarjoura D, Zheng P, Liu Y. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006; 66: 7276-7284. (PMID: 16849577)
72. Fevery S, Billiau AD, Sprangers B, Rutgeerts O, Lenaerts C, Goebels J, Landuyt W, Kasran A, Boon L, Sagaert X, De Wolf-Peeters C, Waer M, Vandenberghe P. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia 2007; 21: 1451-1459. (PMID: 17508005)
73. Met O, Wang M, Pedersen AE, Nissen MH, Buus S, Claesson MH. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett 2006; 231: 247-256. (PMID: 16399226)
74. Leach DR, Krummel MF, Allison JP. Enhancement of anti-tumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736. (PMID: 8596936)
75. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Green-berg NM, Burg MB, Allison JP. Manipulation of T cell co-stimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997; 94: 8099-9103. (PMID: 9223321)
76. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 1999; 96: 15074-15079. (PMID: 10611340)
77. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic model using CTLA-4 blockade. Cancer Res 2000; 60: 2444-2448. (PMID: 10811122)
78. Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso M, Norton L, Allison JP. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 2012; 72: 430-439. (PMID: 22108823)
79. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in anti-tumor therapy reveals alternative pathways for suppression of autoreactive cyto-toxic T lymphocyte responses. J Exp Med 2001; 194: 823-832. (PMID: 11560997)
80. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190: 355-366. (PMID: 10430624)
81. Davila E, Kennedy R, Celis E. Generation of anti-tumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligo-deoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 2003; 63: 3281-3288. (PMID: 12810660)
82. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107: 4275-4280. (PMID: 20160101)
83. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the anti-tumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206: 1717-1725. (PMID: 19581407)
84. Sorensen MR, Holst PJ, Steffensen MA, Christensen JP, Thomsen AR. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 2010; 28: 6757-6764. (PMID: 20682365)
85. Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 1998; 58: 5301-5304. (PMID: 9850053)
86. Paradis TJ, Floyd E, Burkwit J, Cole SH, Brunson B, Elliott E, Gil-man S, Gladue RP. The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma. Cancer Immunol Immunother 2001; 50: 125-133. (PMID: 11419179)
87. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Ala-parthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Sha-habi V. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2011; 61: 1019-1031. (PMID: 22146893)
88. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767. (PMID: 21633166)
89. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059. (PMID: 17704786)
90. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Sch-lemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanello-poulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178. (PMID: 19767732)
91. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9: 353-363. (PMID: 19365408)
92. Shrikant P, Khoruts A, Mescher MF. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-depen-dent mechanism. Immunity 1999; 11: 483-493. (PMID: 10549630)
93. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-322. (PMID: 15057291)
94. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 2008; 13 Suppl 4: 16-25. (PMID: 19001147)
95. Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist 2008; 13 Suppl 4: 10-15. (PMID: 19001146)
96. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723. (PMID: 20525992)
97. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Har-mankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526. (PMID: 21639810)
98. ClinicalTrials.gov. Accessed from: http://clinicaltrials.gov/ct2/home
99. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420. (PMID: 19934295)
100. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cyto-toxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol 2005; 23: 8968-8977. (PMID: 16204013)
101. Gomez-Navarro J, Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski TF, Pavlov D, Bulahagui C, Ribas A, Camacho LH. Survival of patients with metastatic melanoma with the anti-CTLA4 monoclonal antibody CP-675,206 in a phase I/II study [abstract]. J Clin Oncol 2007; 25 Suppl 18: Abstract 8524.
102. Ribas A, Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski TF, Pavlov D, Bulahagui C, Gomez-Navarro J, Camacho LH. Results of a phase II trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients with advanced melanoma [abstract]. J Clin Oncol 2007; 25 Suppl 18: Abstract 3000.
103. Ribas A, Hauschild A, Kefford R, Gomez-Navarro J, Pavlov D, Marshall D. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [oral] [abstract]. J Clin Oncol 2008; 20 Suppl 15: Abstract LBA9011.
104. Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 2010; 3: 15-25. (PMID: 20616954)
105. Wallis N, Bulanhagui CA, Dorazio PC, Healey DI, Marshall MA, Liang JQ, Pavlov D, Gomez-Navarro J. Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer. J Clin Oncol 2008; 20 Suppl 15: Abstract 3040.
106. AstraZeneca unit in-licenses Pfizer drug candidate tremelimumab [press release]. Accessed from: http://www.thepharmaletter.com/ file/107799/astrazeneca-unit-in-licenses-pfizer-drug-candidate-tremelimumab.html
107. Melero I, Sangro B, Riezu-Boj JI, Iñarrairaegui M, Lasarte JJ, Sarobe P, Larrea E, Prieto J. Antiviral and anti-tumoral effects of the anti-CTLA4 agent tremelimumab in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C virus (HCV) infection: Results from a phase II clinical trial. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, Mar 31-Apr 4, 2012, Chicago, IL. Cancer Res 2012; 72 (8 Suppl 1): Abstract 4387.
108. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010; 37: 473-484. (PMID: 21074063)
109. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logo-thetis C, Sharma P. CTLA-4 blockade increases IFNy-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008; 105: 14987-14992. (PMID: 18818309)
110. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 2008; 6: 22. (PMID: 18452610)
111. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilim-umab in advanced melanoma. J Transl Med 2011; 9: 204. (PMID: 22123319)
112. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 2011; 108: 16723-16728. (PMID: 21933959)
113. Petrausch U, Haley D, Miller W, Floyd K, Urba WJ, Walker E. Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data. Cytometry A 2006; 69: 1162-1173. (PMID: 17089357)